Neprisol Injection

Adult administration

Generally, administer 250 to 500 mL intravenously (1.6 to 3.2 g of nitrogen, 13.4 to 26.8 g of essential amino acids) per day. When providing caloric sources simultaneously, use 250 mL of this product mixed aseptically with 500 mL of 70% glucose (this product diluted to 1.8%, glucose to 47%). The administration rate is usually started at 20 to 30 mL per hour for the first dose, increasing to a maximum of 60 to 100 mL.

Child administration

The initial total daily amount should be reduced and increased slowly, not exceeding 1 g of essential amino acids per kg of body weight per day.

This medication must be used strictly according to a physician's instructions. It should not be used in patients with hepatic coma or those at risk of hepatic coma, patients with severe electrolyte imbalances, patients with decreased blood circulation, patients with hyperammonemia, patients with congenital amino acid metabolism disorders, patients with severe heart failure, and patients with excess fluid supply. Use with caution in patients with congestive heart failure, children, underweight children, patients dependent on this medication, and patients with gastrointestinal bleeding or at risk of hyperammonemia. This product contains sodium bisulfite, which may cause allergic reactions or asthma attacks, especially in asthma patients. During use, side effects such as itching, rash, nausea, vomiting, chest discomfort, and palpitations may occur, and metabolic acidosis may develop with rapid large-volume administration. Additionally, liver function tests may show elevated levels, and blood urea and ammonia concentrations may change, along with the risk of thrombophlebitis. If symptoms of hyperammonemia occur, administration should be stopped immediately and the hydration and electrolyte status, as well as blood tests, should be checked regularly. Especially in children or patients with impaired liver function, a specially formulated solution must be used, and diabetic patients should pay attention to blood sugar control. This medication can produce toxic substances when mixed with other drugs, so it should preferably be used alone and only in conjunction with confirmed compatible medications when necessary. In the case of overdose, if symptoms occur, administration should be stopped or gradually reduced. Care should be taken to maintain electrolyte balance during administration, and it should be infused slowly intravenously while ensuring strict aseptic conditions. Do not use the solution if it is cloudy or discolored, and storage should be limited to 24 hours in a refrigerator; leftover solution should not be reused. Finally, do not use if there are any abnormalities with the packaging or solution, and pay attention to the safe handling and storage of the drug.

Serious side effects

Generalized urticaria, severe edema (including edema related to amino acid overload, which may occur occasionally), difficulty breathing and asthma attacks, altered consciousness due to hyperammonemia, delayed verbal response or alertness, reduced voluntary movements and speech, impaired arithmetic ability, cognitive impairment

Mild side effects

• Generalized itching
• rash
• nausea
• vomiting
• loss of appetite
• chest discomfort
• palpitations
• metabolic acidosis
• elevated AST/ALT
• elevated BUN

This medication should be stored in a sealed container to prevent air or moisture from entering, and it is recommended to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature. Storing it this way helps maintain the effectiveness of the medication for a longer period.

Appearance

An injection filled with a colorless to pale yellow transparent solution in a colorless transparent glass or plastic container

Package unit

250 mL/bottle, 250 mL/bag, 500 mL/bottle